Ferrannini, E <br/><br/>
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Aug 2013 
 - 721-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12081  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Argentina--epidemiology<br/>Benzhydryl Compounds--administration & dosage<br/>Blood Glucose<br/>Body Weight<br/>Diabetes Mellitus, Type 2--blood<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Europe--epidemiology<br/>Female<br/>Glucosides--administration & dosage<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Hypoglycemic Agents--administration & dosage<br/>Male<br/>Metformin--administration & dosage<br/>Middle Aged<br/>Nasopharyngitis--chemically induced<br/>Republic of Korea--epidemiology<br/>Russia--epidemiology<br/>Sodium-Glucose Transporter 2 Inhibitors<br/>Taiwan--epidemiology<br/>Thirst<br/>Treatment Outcome<br/>Ukraine--epidemiology<br/>Urination Disorders--chemically induced<br/>Weight Loss